Patents Assigned to Autoimmune Technologies, LLC
-
Publication number: 20220280618Abstract: The present invention is directed to antibodies binding to and neutralizing Candida and methods for use thereof.Type: ApplicationFiled: July 28, 2020Publication date: September 8, 2022Applicants: The Administrators of the Tulane Educational Fund, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Autoimmune Technologies, LLCInventors: Russell B. WILSON, Hong XIN, James E. ROBINSON
-
Patent number: 10357562Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.Type: GrantFiled: July 17, 2015Date of Patent: July 23, 2019Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLCInventors: Robert Francis Garry, Luis Manuel Branco, Bruce Alan Bunnell, Russell B. Wilson, Samuel E. Hopkins
-
Patent number: 10330686Abstract: An assay method for detecting antipolyvinyl alcohol (anti-PVAL) antibodies in test samples, such as serum, is described. The method comprises combining a sample to be tested for an anti-PVAL antibody with polyvinyl alcohol (PVAL) to form a binary complex of the PVAL with an anti-PVAL antibody in the sample, followed by reacting an indicator reagent with the binary complex to form a labeled ternary complex, and then detecting the presence or absence of the ternary complex in the sample. Kits for performing the test are also described.Type: GrantFiled: October 20, 2016Date of Patent: June 25, 2019Assignee: Autoimmune Technologies, LLCInventors: Russell B. Wilson, Kevin David Simpson
-
Patent number: 10137194Abstract: Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such asbovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.Type: GrantFiled: May 10, 2017Date of Patent: November 27, 2018Assignees: The Admininstrators of the Tulane Educational Fund, Autoimmune Technologies, LLCInventors: Robert Francis Garry, Russell B. Wilson
-
Patent number: 9725487Abstract: The present invention provides compositions and methods for treating a measles virus infection. A pharmaceutical composition comprises a polypeptide in a biocompatible pharmaceutical carrier, in which the polypeptide consists of at least a portion of SEQ ID NO: 5 or SEQ ID NO: 6. A method embodiment comprises administering the polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a measles infection.Type: GrantFiled: May 13, 2015Date of Patent: August 8, 2017Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLCInventors: Robert F. Garry, Russell B. Wilson
-
Patent number: 9649375Abstract: Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.Type: GrantFiled: March 14, 2013Date of Patent: May 16, 2017Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC.Inventors: Robert Francis Garry, Russell B. Wilson
-
Patent number: 9353157Abstract: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.Type: GrantFiled: December 10, 2013Date of Patent: May 31, 2016Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLCInventors: Robert F. Garry, Russell B. Wilson
-
Patent number: 9101597Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.Type: GrantFiled: March 14, 2013Date of Patent: August 11, 2015Assignees: The Administration of the Tulane Educational Fund, Autoimmune Technologies, LLCInventors: Robert Francis Garry, Luis Manuel Branco, Bruce Alan Bunnell, Russell B. Wilson, Samuel E. Hopkins
-
Patent number: 9056900Abstract: The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.Type: GrantFiled: August 8, 2013Date of Patent: June 16, 2015Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLC.Inventors: Robert F. Garry, Russell B. Wilson
-
Publication number: 20140194347Abstract: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.Type: ApplicationFiled: December 10, 2013Publication date: July 10, 2014Applicants: Autoimmune Technologies, LLC, The Administrators of the Tulane Educational FundInventors: Robert F. GARRY, Russell B. WILSON
-
Publication number: 20140045743Abstract: The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.Type: ApplicationFiled: August 8, 2013Publication date: February 13, 2014Applicants: Autoimmune Technologies, LLC, The Administrators of the Tulane Educational FundInventors: Robert F. GARRY, Russell B. WILSON, I
-
Patent number: 8604165Abstract: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.Type: GrantFiled: June 25, 2008Date of Patent: December 10, 2013Assignees: The Administrators of the Tulane Educational Fund, Autoimmune Technologies, LLCInventors: Robert F. Garry, Russell B. Wilson
-
Patent number: 8598116Abstract: The present invention provides methods for the treatment of an ongoing influenza infection by administering a polypeptide to a subject suffering from an influenza infection. The polypeptide consists of SEQ ID NO: 4. The present invention also provides a method of interfering with fusion of an influenza virus envelope with a host cell membrane by contacting the host cell with a polypeptide consisting of SEQ ID NO: 4.Type: GrantFiled: May 29, 2012Date of Patent: December 3, 2013Assignees: The Administrators of the Tulane, Educational Fund and Autoimmune Technologies, LLCInventors: Robert F. Garry, Russell B. Wilson
-
Patent number: 8222204Abstract: The present invention provides compositions useful for treating or preventing influenza infections. The composition comprises an isolated polypeptide including a sequence of at least 8 contiguous amino acid residues of the fusion initiation region (FIR) of an influenza hemagglutinin 2 protein or a peptide analog of the sequence. The FIR is a segment of the full length hemagglutinin 2 protein which is bounded by an amino-terminal region within the amino-terminal alpha-helix thereof and a carboxy terminus within the carboxy-terminal alpha-helix thereof, with a cysteine loop therebetween. The amino-terminal region of the FIR comprises a portion of the final 10 to 20 amino acid residues of the amino-terminal alpha-helix of the hemagglutinin 2 protein, and includes 3 or 4 hydrophobic amino acid residues, a positively-charged amino acid residue, a negatively-charged amino acid residue, and an aromatic amino acid residue.Type: GrantFiled: February 17, 2009Date of Patent: July 17, 2012Assignee: The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLCInventors: Robert F. Garry, Russell B. Wilson